The FREVIVA clinical trial is a Phase III study evaluating the effectiveness and safety of Frexalimab, an investigational monoclonal antibody targeting the CD40 ligand, in individuals with non-relapsing secondary-progressive multiple sclerosis (SPMS). The trial aims to determine whether Frexalimab can slow disease progression compared to a placebo. Participants will receive monthly intravenous infusions for up to 51 months, with the option for at-home treatment after six months. The study involves nationwide locations and multiple institutions, with eligibility criteria available on the study website. Participants will be closely monitored for potential benefits and risks, with the opportunity to join a long-term safety study after completing the trial.
